Harvard Bioscience
HBIO
85 hedge funds and large institutions have $79.2M invested in Harvard Bioscience in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 36 reducing their positions, and 9 closing their positions.
0.15% less ownership
Funds ownership: 6.92% → 6.77% (-0.15%)
4% less capital invested
Capital invested by funds: $82.3M → $79.2M (-$3.13M)
2% less funds holding
Funds holding: 87 → 85 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
25% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 36
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$1.76M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.34M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$874K |
| 4 |
Renaissance Technologies
New York
|
+$737K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$490K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
-$2.52M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.21M |
| 3 |
RA
Royce & Associates
New York
|
-$945K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$725K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$408K |
HBIO Hedge Fund Activity: Q3 2020 in Review
85 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2020, worth a combined $79.2M — down 3.8% from $82.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of HBIO and 7 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 27 added.
The largest buyer was Punch & Associates Investment Management, adding an estimated $1.76M. The largest seller was Dalton, Greiner, Hartman, Maher & Co, cutting an estimated $2.52M.
- 85 institutional investors held Harvard Bioscience (HBIO) as of Q3 2020, down from 87 in Q2 2020.
- Funds reported $79.2M of Harvard Bioscience stock for Q3 2020, down 3.8% quarter-over-quarter.
- 7 funds opened new Harvard Bioscience positions in Q3 2020 and 9 closed out, a net change of -2 holders.
- The largest Harvard Bioscience buyer in Q3 2020 was Punch & Associates Investment Management, an estimated $1.76M added.
- The largest Harvard Bioscience seller in Q3 2020 was Dalton, Greiner, Hartman, Maher & Co, an estimated $2.52M sold.
Based on aggregated 13F filings for Q3 2020.